A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Comparator: odanacatib|DRUG: Comparator: placebo
Sponsor: Merck Sharp & Dohme LLC